CA72-4 在卵巢子宫内膜异位症与上皮性卵巢癌鉴别诊断中的应用价值
Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer?
机构信息
Department of Molecular Medicine, "Sapienza" University of Rome, Policlinico Umberto I, Viale Regina Elena 324, 00161 Rome, Italy.
出版信息
Dis Markers. 2013;35(5):331-5. doi: 10.1155/2013/984641. Epub 2013 Sep 22.
BACKGROUND
Surgical excision of ovarian endometriomas in patients desiring pregnancy has recently been criticized because of the risk of damage to healthy ovarian tissue and consequent reduction of ovarian reserve. A correct diagnosis in cases not scheduled for surgery is therefore mandatory in order to avoid unexpected ovarian cancer misdiagnosis. Endometriosis is often associated with high levels of CA125. This marker is therefore not useful for discriminating ovarian endometrioma from ovarian malignancy. The aim of this study was to establish if the serum marker CA72-4 could be helpful in the differential diagnosis between ovarian endometriosis and epithelial ovarian cancer.
METHODS
Serums CA125 and CA72-4 were measured in 72 patients with ovarian endometriomas and 55 patients with ovarian cancer.
RESULTS
High CA125 concentrations were observed in patients with ovarian endometriosis and in those with ovarian cancer. A marked difference in CA72-4 values was observed between women with ovarian cancer (71.0%) and patients with endometriosis (13.8%) (P < 0.0001).
CONCLUSIONS
This study suggests that CA72-4 determination can be useful to confirm the benign nature of ovarian endometriomas in women with high CA125 levels.
背景
由于担心手术切除卵巢子宫内膜异位症会损伤健康的卵巢组织，导致卵巢储备功能下降，因此最近有研究对有生育要求的患者行卵巢子宫内膜异位症手术切除术提出了批评。因此，对于不计划手术的患者，正确的诊断是必不可少的，以避免对卵巢癌的误诊。子宫内膜异位症常伴有高水平的 CA125。因此，该标志物不能用于区分卵巢子宫内膜异位症和卵巢恶性肿瘤。本研究旨在确定血清标志物 CA72-4 是否有助于鉴别卵巢子宫内膜异位症和上皮性卵巢癌。
方法
检测 72 例卵巢子宫内膜异位症患者和 55 例卵巢癌患者的血清 CA125 和 CA72-4。
结果
卵巢子宫内膜异位症患者和卵巢癌患者的 CA125 浓度较高。卵巢癌患者（71.0%）和子宫内膜异位症患者（13.8%）的 CA72-4 值差异有统计学意义（P < 0.0001）。
结论
本研究表明，对于 CA125 水平升高的患者，CA72-4 测定有助于证实卵巢子宫内膜异位症的良性性质。
Zotero 插件